Pimodivir

Summary

Pimodivir (CHEMBL3318007) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including influenza and liver disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 19
• Chemistry: 399.4 Da · C20H19F2N5O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3318007
Name	Pimodivir
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	67286591
Molecular formula	C20H19F2N5O2
Molecular weight	399.4
InChIKey	JGPXDNKSIXAZEQ-SBBZOCNPSA-N

SMILES: C1CC2CCC1[C@@H]([C@H]2NC3=NC(=NC=C3F)C4=CNC5=C4C=C(C=N5)F)C(=O)O

IUPAC name: (2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid

Also known as: JNJ - 63623872 - ZCD, JNJ-63623872, JNJ-872, JNJ63623872, JNJ872, Pimodivir, VX -787, VX-787, Vx-787 anhydrous base, PIMODIVIR, C0088736

Parent form; salt/anhydrous children: CHEMBL3989964

Patent coverage: 44 distinct patent families (144 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 88 (61%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Glycogen synthase kinase-3, Glycogen synthase kinase-3 beta, Polymerase basic protein 2.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P03428	9.22	EC50	0.6	nM	CHEMBL_ACT_18943842
P03428	8.4	IC50	4	nM	CHEMBL_ACT_25709298
P03428	7.27	Kd	54	nM	CHEMBL_ACT_24509298
GSK3B	5.8	Ki	1600	nM	CHEMBL_ACT_15046776
GSK3A	5.8	Ki	1600	nM	CHEMBL_ACT_15173624

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
influenza	2	MONDO:0005812	EFO:0007328
liver disorder	1	MONDO:0005154	EFO:0001421
chronic kidney disease	1	MONDO:0005300	MONDO:0024327

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
PHASE1	13
PHASE2	3
PHASE3	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03376321	PHASE3	TERMINATED	A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection
NCT03381196	PHASE3	TERMINATED	A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications
NCT01561807	PHASE2	COMPLETED	A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus
NCT02342249	PHASE2	COMPLETED	Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects
NCT02532283	PHASE2	COMPLETED	A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection
NCT02262715	PHASE1	COMPLETED	A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir
NCT02418559	PHASE1	COMPLETED	A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants
NCT02448004	PHASE1	COMPLETED	Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants
NCT02595268	PHASE1	COMPLETED	A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants
NCT02652650	PHASE1	COMPLETED	A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone
NCT02658825	PHASE1	COMPLETED	A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants
NCT02659735	PHASE1	COMPLETED	A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation
NCT02860806	PHASE1	COMPLETED	Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults
NCT02888327	PHASE1	COMPLETED	A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872
NCT03023852	PHASE1	COMPLETED	A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants
NCT03768609	PHASE1	COMPLETED	A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults
NCT03816631	PHASE1	COMPLETED	A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment
NCT03947814	PHASE1	TERMINATED	A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment
NCT03834376	Not specified	NO_LONGER_AVAILABLE	Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).